Support Alert

Drug safety update: Naltrexone/bupropion (Mysimba)

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a drug safety update that patients should be advised that naltrexone/bupropion has been associated with adverse reactions such as dizziness or somnolence, which can affect ability to drive, operate machinery, or perform dangerous tasks. Advise patients not to drive if they suspect their ability may be impaired. 

Loading...

Renew for 2022

Your dedication to patient care has made us proud during 2021.

That's why you can count on us to represent your interests and support your efforts every step of the way in 2022.

RENEW YOUR MEMBERSHIP TODAY